This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma

This study has been completed.
Sponsor:
Collaborator:
Amgen
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01351623
First received: May 9, 2011
Last updated: March 15, 2017
Last verified: March 2017
Results First Received: January 3, 2017  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: No masking;   Primary Purpose: Treatment
Condition: Multiple Myeloma
Intervention: Drug: Carfilzomib

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Carfilzomib

A single arm, open-label, single institution phase 2 clinical trial is planned.

Carfilzomib: Following enrollment patients will be treated with single agent infusional carfilzomib at 56mg/m2. Carfilzomib will be administered intravenously over 30 minutes on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses during the first cycle.


Participant Flow:   Overall Study
    Carfilzomib
STARTED   44 
COMPLETED   35 
NOT COMPLETED   9 
Protocol Violation                2 
Adverse Event                4 
Withdrawal by Subject                1 
Death                2 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Carfilzomib

A single arm, open-label, single institution phase 2 clinical trial is planned.

Carfilzomib: Following enrollment patients will be treated with single agent infusional carfilzomib at 56mg/m2. Carfilzomib will be administered intravenously over 30 minutes on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses during the first cycle.


Baseline Measures
   Carfilzomib 
Overall Participants Analyzed 
[Units: Participants]
 44 
Age 
[Units: Years]
Median (Full Range)
 63 
 (45 to 86) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
 
Female      25  56.8% 
Male      19  43.2% 
Ethnicity (NIH/OMB) 
[Units: Participants]
Count of Participants
 
Hispanic or Latino      9  20.5% 
Not Hispanic or Latino      34  77.3% 
Unknown or Not Reported      1   2.3% 
Race (NIH/OMB) 
[Units: Participants]
Count of Participants
 
American Indian or Alaska Native      0   0.0% 
Asian      2   4.5% 
Native Hawaiian or Other Pacific Islander      0   0.0% 
Black or African American      18  40.9% 
White      23  52.3% 
More than one race      0   0.0% 
Unknown or Not Reported      1   2.3% 
Region of Enrollment 
[Units: Participants]
 
United States   44 


  Outcome Measures

1.  Primary:   To Evaluate the Best Overall Response Rate (ORR)   [ Time Frame: 2 years ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Nikoletta Lendvai, MD
Organization: Memorial Sloan Kettering
phone: (212) 639-3368
e-mail: lendvain@mskcc.org


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT01351623     History of Changes
Other Study ID Numbers: 10-228
Study First Received: May 9, 2011
Results First Received: January 3, 2017
Last Updated: March 15, 2017